You are currently logged into
Hep Directory - My Account or Log Out
Hep Hep
  • Home
  • Basics
    • Basics
    • Introduction
    • Hepatitis A Virus
    • Hepatitis B Virus
    • Hepatitis C Virus
    • NAFLD/NASH
    • Alcoholic Liver Disease
    • Autoimmune Hepatitis
    • Primary Biliary Cholangitis
  • News
    • News
    • Newsfeed
    • Science News
    • Features
    • Conferences
    • Hep Stories
    • Hep Slideshows
    • Hep TV
    • By Author
    • RSS Links
  • Hot Topics
    • Hot Topics
    • Opioids
    • Hep A Outbreak Map
    • Newly Diagnosed
    • Help Paying for Treatment
    • Hepatitis C Testing
    • Hepatitis C Medications
    • Hepatitis B Testing
    • Hepatitis B Treatment
  • Magazine
    • Magazine
    • Current Issue
    • Archives
    • Digital Editions
    • Bulk Subscriptions
    • Email Newsletter
  • Blogs
    • Blogs
    • Recent Posts
    • Browse Bloggers
    • RSS Links
  • Community
    • Community
    • Hep Stories
    • Hep Forums
    • Polls
    • Surveys
    • Ask Hep
    • Services Directory
    • Calendar
    • Bookstore
  • About Us
    • About Us
    • About Us
    • Masthead
    • Awards
    • Advertise
    • Contact Us
  • Facebook
  • Twitter

© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

© 2021 Smart + Strong.
All Rights Reserved.
Terms of use and
Your privacy.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.

Advertisement

Share


Twitter
Facebook
Pinterest
Tumblr
Email

#dialysis

Tweet
  • Share

The Liver Meeting 2018 Roundup

A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco

Mavyret Is Safe for Those With Severely Impaired Kidneys

A recent analysis of two studies of AbbVie’s hepatitis C regimen showed good results in this population.

For Those on Dialysis, Epclusa Is an Option for Hepatitis C Treatment

In a recent study of Gilead’s Epclusa (sofosbuvir/velpatasvir), 92 percent of participants were on dialysis and 29 percent had cirrhosis.

Transplanting Hep–Positive Kidneys Is Cost-Effective

Researchers crunched the numbers for transplanting kidneys from donors with hep C and then treating the virus in the recipient.

Treating Hepatitis C Among Those on Dialysis Lowers Risk of Death

This is according to a large study of Swedish people with hep C and chronic kidney disease.

How Does Hepatitis C Affect Non-Liver-Related Health?

And can treating the virus reduce the risk of chronic kidney and cardiovascular diseases as well as the risk of death from such causes?

Advertisement

Stay Logged In?

You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.

You Have Been Logged Out

Click here to log back in.